Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Incyte Corporation
INCY
NASDAQ·Healthcare·Biotechnology·Mkt cap $22.7B
$116.86
▲ +2.68%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$66.85 - $118.69
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 67.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary drug discovery platform
- Diverse clinical-stage product pipeline
- Strategic pharmaceutical collaborations
- Focus on precision medicine technologies
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Expanding oncology treatment portfolio
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Strong
+18.6% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INCY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 27, 2026
APR 28, 2026
Reported EPS of $1.81 vs $1.38 consensus (+31.2% surprise). Revenue of $1.3B vs $1.2B expected (+4.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+31.2%
Next: Apr 27, 2026
Revenue trend · last 8Q
—
—
+16%
+20%
+16%
+20%
+28%
+21%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.0B
$1.1B
$1.2B
$1.1B
$1.2B
$1.4B
$1.5B
$1.3B
Margins · last 8Q
Gross
91.8%
Operating
23.7%
Profit
23.8%
Wall Street consensus
14 analysts · 29% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
29%
Hold
71%
Sell
0%
Median Price Target
$94.50
▼ -19.1% vs $116.86
Latest: UBS · Jun 26, 2026
2 analysts covering
vs Industry
How INCY stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related